"Antigens, CD19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
| Descriptor ID |
D018941
|
| MeSH Number(s) |
D23.050.301.264.035.119 D23.050.301.264.051.119 D23.050.301.500.600.200 D23.050.705.552.600.200 D23.101.100.110.119 D23.101.100.150.119
|
| Concept/Terms |
Antigens, CD19- Antigens, CD19
- CD19 Antigens
- B Cell Antigen CD19
- CD19 Antigen
- Antigen, CD19
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD19".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Antigens, CD19 [D23.050.301.264.035.119]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- Antigens, CD19 [D23.050.301.264.051.119]
- Histocompatibility Antigens [D23.050.301.500]
- Minor Histocompatibility Antigens [D23.050.301.500.600]
- Antigens, CD19 [D23.050.301.500.600.200]
- Isoantigens [D23.050.705]
- Histocompatibility Antigens [D23.050.705.552]
- Minor Histocompatibility Antigens [D23.050.705.552.600]
- Antigens, CD19 [D23.050.705.552.600.200]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Antigens, CD19 [D23.101.100.110.119]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- Antigens, CD19 [D23.101.100.150.119]
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD19".
This graph shows the total number of publications written about "Antigens, CD19" by people in this website by year, and whether "Antigens, CD19" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 3 | 3 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 2 | 1 | 3 |
| 2016 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 3 | 3 |
| 2021 | 2 | 3 | 5 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 5 | 7 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, CD19" by people in Profiles.
-
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025 Mar 11; 9(5):1232-1241.
-
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025 Jan 11; 405(10473):127-136.
-
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.
-
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024 Dec 12; 391(23):2219-2230.
-
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 10 22; 8(20):5346-5354.
-
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2025 Feb 10; 43(5):558-566.
-
BsAbs before CD19 CAR-T: full speed ahead! Blood. 2024 07 18; 144(3):249-251.
-
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis. Leukemia. 2024 Jul; 38(7):1564-1569.
-
Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2024 Jun; 30(6):584.e1-584.e13.
-
Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2023 09 12; 7(17):4765-4772.